Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


0.00 (0.00%)

Market Cap$9,319,252,035

04/21/17  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017 04/06/17

Read more

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 04/03/17

Read more


1st Quarter 2017 Financial Results04/27/17 4:30 p.m. ETView eventBarclays Global Healthcare Conference 201703/15/17 10:45 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources